Skip to content

Study · Non-randomized trial · 2000

4 results

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.

Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ

The Journal of clinical endocrinology and metabolism1 Jun 2000Cited by 196 (Europe PMC)

PMID10852440 (opens in a new tab)DOI10.1210/jcem.85.6.6614 (opens in a new tab)PepBankPUB-10852440
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, PTH increased spine BMD by 7.1 +/- 5.6% during the first year, with all doses combined.

    In plain wordsIn women with osteoporosis, spine bone density increased by 7.1% during the first year of PTH.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseSpine BMD change
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50, 75, or 100 microg · 1 yearAs given in this study (human).

    Measurements

    Spine BMD change
    7.1%
    all PTH doses combined

    Source sentences

    Summary
    During the first year, changes in BMD (mean +/- SD) in women receiving PTH (all doses combined) were 7.1 +/- 5.6% (spine), 0.3 +/- 6.2% (femoral neck), and -2.3 +/- 3.3% (total body).
    1 context sentence
    Summary · context
    Sixty-six postmenopausal osteoporotic women were treated for 1 yr with 50, 75, or 100 microg recombinant human PTH-(1-84) or placebo, and then were given 10 mg alendronate daily for an additional year.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, PTH changed femoral neck BMD by 0.3 +/- 6.2% during the first year.

    In plain wordsIn women with osteoporosis, thigh bone neck density changed by 0.3% during the first year of PTH.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseFemoral neck BMD change
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50, 75, or 100 microg · 1 yearAs given in this study (human).

    Measurements

    Femoral neck BMD change
    0.3%
    all PTH doses combined

    Source sentences

    Summary
    During the first year, changes in BMD (mean +/- SD) in women receiving PTH (all doses combined) were 7.1 +/- 5.6% (spine), 0.3 +/- 6.2% (femoral neck), and -2.3 +/- 3.3% (total body).
    1 context sentence
    Summary · context
    Sixty-six postmenopausal osteoporotic women were treated for 1 yr with 50, 75, or 100 microg recombinant human PTH-(1-84) or placebo, and then were given 10 mg alendronate daily for an additional year.
  3. 03HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, PTH decreased total body BMD by 2.3 +/- 3.3% during the first year.

    In plain wordsIn women with osteoporosis, total body bone density decreased by 2.3% during the first year of PTH.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    DecreaseTotal body BMD change
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50, 75, or 100 microg · 1 yearAs given in this study (human).

    Measurements

    Total body BMD change
    −2.3%
    all PTH doses combined

    Source sentences

    Summary
    During the first year, changes in BMD (mean +/- SD) in women receiving PTH (all doses combined) were 7.1 +/- 5.6% (spine), 0.3 +/- 6.2% (femoral neck), and -2.3 +/- 3.3% (total body).
    1 context sentence
    Summary · context
    Sixty-six postmenopausal osteoporotic women were treated for 1 yr with 50, 75, or 100 microg recombinant human PTH-(1-84) or placebo, and then were given 10 mg alendronate daily for an additional year.
  4. 04HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, all measured bone turnover markers increased during PTH treatment.

    In plain wordsIn women with osteoporosis, all measured bone turnover markers increased during PTH treatment.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseBone turnover markers
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    50, 75, or 100 microgAs given in this study (human).

    Source sentences

    Summary
    All markers of bone turnover increased during treatment with PTH
    1 context sentence
    Summary · context
    Sixty-six postmenopausal osteoporotic women were treated for 1 yr with 50, 75, or 100 microg recombinant human PTH-(1-84) or placebo, and then were given 10 mg alendronate daily for an additional year.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.